PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Coll Cardiol. Author manuscript; available in PMC 2010 September 22.
Published in final edited form as:
PMCID: PMC2775806
NIHMSID: NIHMS154839

Cardiovascular Disease in Adult and Pediatric HIV/AIDS

It may surprise some to learn that the National Heart, Lung, and Blood Institute (NHLBI) has been funding research on the cardiovascular complications of HIV/AIDS for well over twenty years. We present a brief overview and an update on NHLBI-funded cardiovascular research in HIV/AIDS.

Since it was first recognized clinically in 1981, HIV/AIDS has gone from a fatal syndrome to a chronic disease in individuals receiving highly active antiretroviral therapy (HAART). Though the first antiretroviral agent, zidovudine (AZT), was introduced into the market in 1987, the era of HAART really began after the marketing approval of the first protease inhibitor in December of 1995. Much has been reported about the relationship between HAART and cardiovascular disease (CVD), but it is this combination antiretroviral therapy that has allowed the overall mortality of HIV to decline dramatically and life expectancy to increase to the point where CVD-related deaths now represent an increasing proportion of the deaths in HIV-infected patients.

Even prior to the era of HAART researchers noted that untreated HIV-infected patients had altered lipid profiles, including lowered high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels, elevated triglyceride levels, and anthropomorphic changes such as increased visceral fat and decreased subcutaneous fat (1,2). With the widespread use of HAART, the contribution of drug-related metabolic and anthropometric alterations to an increased risk for CVD took on an even greater significance. Several studies in adult populations have provided evidence of an association between HIV infection and its treatment and CVD, including retrospective studies such as the Kaiser Permanente Registry study (3), prospective observational cohort studies such as the Data Collection of Adverse Events of Anti-HIV Drugs (DAD) study (4,5), and prospective randomized clinical trials such as the Strategies for Management of Antiretroviral Therapy (SMART) trial (6). Though myriad class-specific and non-class specific effects on lipid profiles, glucose levels and insulin sensitivity, and body composition have been reported with various antiretroviral agents, there is no question that the use of HAART to ensure adequate viral suppression is paramount to the successful clinical management of HIV-infected patients.

The currently available evidence from various studies suggests that though the overall cardiovascular event rate is low, there is an excess risk of cardiovascular events in HIV-infected persons compared to non-HIV infected individuals. Evidence suggests that HIV-infected individuals on HAART regimens are at increased risk of dyslipidemia, ischemic heart disease (7), and myocardial infarction, particularly if the HAART regimen contains a protease inhibitor (8, 9). While lipid lowering therapies are a routine element of cardiovascular risk reduction in the general population, HIV-infected persons may not be receiving lipid lowering therapies even when indicated. A recent report showed that among those meeting the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) criteria (10), there was a disparity in receipt of lipid lowering agents among HIV-infected veterans compared to HIV-uninfected veterans (15.4% vs. 37.9% p <0.01) (11). In 2003 the Infectious Diseases Society of America (IDSA) and the Adult AIDS Clinical Trials Group (AACTG) issued an updated version of “Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus-Infected Adults Receiving Antiretroviral Therapy” (http://www.idsociety.org/content.aspx?id=9202#md) (12). HIV-infected patients may have special issues, such as co-infection with hepatitis C, seemingly complicated medication regimens, unusually high triglyceride levels, or the need to gain weight yet achieve lower lipid levels; but, the approach to the management of their dyslipidemia is essentially the same as that for the general population, including starting with non-drug and dietary modalities. If lipid-lowering agents are indicated, navigating the sea of potential drug-drug interactions with the HAART regimen can be challenging, but this should not preclude the use of drugs such as statins or fibrates in HIV-infected patients. Getting to target LDL goals can and should be accomplished by the Cardiologist working closely with the Infectious Diseases specialist (13).

Antiretroviral drugs are the cornerstone of HIV/AIDS management and they may be associated with insulin resistance and dyslipidemia, but they are not the only factors likely involved in the increased CVD risk seen in HIV-infected patients. Traditional risk factors may be increased in these patients, such as increased rates of smoking; HIV itself may affect traditional risk factors, including lipid profiles; and/or there may be increased underlying inflammation or endothelial dysfunction. How HIV affects the heart and vasculature as a whole in the presence of anti-retroviral therapy (ART) is not fully known, but left ventricular dysfunction is clinically common and pulmonary arterial hypertension can occur in 1 out of every 200 HIV+ adults, most often in patients without advanced HIV disease. In contrast to primary pulmonary hypertension (PPH) where there is a female predominance, males are more affected by pulmonary arterial hypertension associated with HIV infection (HIV-PAH). HIV-PAH shares several clinical and pathological features with PPH, but has decreased 1-year survival rates (51%) compared to rates in a National Institutes of Health registry for PPH (68%) (14). HIV-PAH patients have worse survival than HIV-infected patients without PAH and often die from conditions related to the pulmonary hypertension, not from the HIV infection per se. Therefore, prompt diagnosis and initiation of specific therapy such as a prostacyclin (epoprostenol) or the dual endothelin receptor antagonist bosentan is crucial (15). Isolated diastolic dysfunction may be an early sign of cardiovascular disease in both the general population and HIV-infected patients. A recent albeit small study reported an unexpectedly high prevalence of diastolic dysfunction (37%) in a cohort of young (median age=38 years), asymptomatic HIV-infected patients at otherwise low risk for cardiovascular disease (16). Consequently, although there are currently no recommendations for routine screening echocardiograms in this population, these data suggest such additional evaluations may be warranted in particular patients.

Research conducted prior to the HAART era demonstrated that HIV infection itself can cause nonatherosclerotic structural and functional injury to the heart and vasculature. In one of the first reports of cardiac disease in HIV-infected children, Lipshultz and colleagues reported abnormalities of left ventricular shortening, afterload, and contractility. Pericardial effusion, arrhythmias, and pathologic evidence of pericarditis, myocarditis, and inflammation of the conduction system were also observed (17). To address the high rates of cardiac complications seen in the HIV/AIDS epidemic, the NHLBI initiated the Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) study in 1990 (18). The P2C2 HIV study was a prospective, observational study that enrolled HIV-infected children from 1990 to 1993 with follow-up to 10 years of age. The study documented cardiac complications as a common feature of HIV disease in children. The five-year cumulative incidence of depressed shortening fraction was 28%, the incidence of left ventricular end-diastolic dilation was 22%, and the incidence of heart failure and/or use of cardiac medications was 29% (19). Decreased left ventricular shortening and increased left ventricular wall thickness were found to be predictive of mortality even after adjusting for CD4 count and encephalopathy (20).

One of the great successes of HAART is the significant decrease in vertical transmission of HIV from mother to child, but this has led to an increasing cohort of antiretroviral therapy-exposed, HIV-negative children. Recent evidence suggests an important role of ART exposure itself in contributing to cardiac disease. The P2C2 HIV study documented diminished left ventricular shortening and contractility at birth in HIV-negative infants born to HIV-positive mothers suggesting that the in utero environment plays an important role in postnatal cardiovascular function. Animal model data have subsequently indicated that nucleoside analog reverse transcriptase inhibitors have a toxic effect on mitochondrial function (21). Further, human studies have demonstrated a depletion of mitochondrial DNA and elevated plasma lactate levels in HIV-negative infants born to zidovudine-treated, HIV-positive mothers (22). Taken together these data suggest potential cardiotoxic effects of ART-exposure in utero. Recently, more direct evidence for this association was provided by the CHAART-I study, in which serial echocardiograms from HIV-negative infants born to ART- or HAART-treated, HIV-positive mothers were compared to HIV-negative infants born to HIV-positive mothers who did not receive perinatal ART or HAART. A preliminary report from that study indicated that fetal exposure to ART/HAART was associated with progressive reductions in LV mass and septal wall thickness (23).

The NHLBI provides co-funding for the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored Pediatric HIV/AIDS Cohort Study (PHACS) network (http://www.nichd.nih.gov/research/supported/phacs.cfm). This network, established in 2005, seeks to advance our understanding of the long-term safety of fetal and infant exposure to prophylactic ART and the effects of perinatally acquired HIV infection in adolescents. The network currently supports two prospective, observational cohort studies (SMARTT and AMP), both with significant cardiovascular components.

The Surveillance Monitoring for ART Toxicities (SMARTT) Study (not to be confused with the SMART study in adults) follows the ART-exposed, but HIV-uninfected, infants and children born to HIV-infected mothers to evaluate for conditions and diagnoses potentially related to in utero and infantile exposure to antiretroviral therapies. The study will identify abnormalities in cardiac function related to ART and/or HIV exposure and examine the utility of serum biomarkers as surrogates of cardiac dysfunction.

The Adolescent Master Protocol (AMP) cohort consists of perinatally exposed, HIV-infected children between the ages of 7 and 16 years and a comparison group of perinatally exposed, HIV-uninfected children. The goal of the study is to evaluate the impact of HIV infection and ART on pre-adolescents and adolescents with perinatal HIV infection. Cardiac function will be evaluated by echocardiography to estimate the prevalence of structural and functional abnormalities in this contemporary cohort of HIV-infected youths.

Recently published work has demonstrated that, similar to adults, the use of protease inhibitors in HIV-infected children is significantly correlated with elevated triglyceride and LDL-cholesterol levels and with reduced HDL-cholesterol levels (24). What this means in terms of cardiovascular risk for HIV-infected children, in the face of lifelong antiretroviral therapy, is unknown.

A State of the Science Conference was convened in Chicago in June 2007 to examine the important unanswered questions surrounding the pathogenesis, detection, and treatment of cardiovascular disease in HIV-infected individuals (25). Following this conference the NHLBI issued a Request for Applications (RFA) for research on the mechanisms and management of cardiovascular and metabolic complications of HIV/AIDS. The NHLBI awarded grants to eight primary research sites and a clinical coordinating center, representing a spectrum of HIV-infected patients and controls including men and women, children, individuals with long-standing infection, and newly diagnosed and/or treatment-naïve patients. Some of the areas under investigation in this program include: the role of oxidative stress and inflammation in elevated CV risk; the effect of antiretroviral therapies on endothelial function and atherosclerosis progression; immune, inflammatory, coagulation, and lipid alterations as mediators of increased atherosclerosis; and assessments of vascular dysfunction due to HIV itself and metabolic parameters. The various studies include standard and novel imaging techniques as well as measurements of endothelial function. The awardees have worked together closely to develop a core set of, and standardized approaches to, laboratory evaluations. The results from these studies are sure to add to our knowledge of cardiovascular disease and its management in HIV/AIDS, with the possibility for advancing our understanding of cardiovascular disease in general.

The NHLBI encourages the continued partnership of basic and clinical cardiovascular and infectious diseases researchers in their effort to tackle the difficult and still unanswered questions of cardiovascular disease in HIV/AIDS.

Footnotes

Disclosures: None

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, Lipoproteins, Triglyceride Clearance, and Cytokines in Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome. J Clin Endocrinol Metab. 1992 May;74(5):1045–52. [PubMed]
2. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquired Immune Defic Syndr Human Retrovirol. 1999 March 1;20(3):228–37. [PubMed]
3. Klein D, Hurley LB, Quesenberry CP, Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2002 August 15;30(5):471–7. [PubMed]
4. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DAD study group Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003 May 23;17(8):1179–93. [PubMed]
5. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20;349(21):1993–2003. [PubMed]
6. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 Nov 30;355(22):2283–96. [PubMed]
7. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007 Jun 15;44(12):1625–31. [PubMed]
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors Among Patients with Human Immunodeficiency Virus Disease. J Clin Endocrinol Metab. 2007 Jul;92(7):2506–12. [PMC free article] [PubMed]
9. DAD Study Group. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 Apr 26;356(17):1723–35. [PubMed]
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001 May 16;285(19):2486–97. [PubMed]
11. Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. J Gen Intern Med. 2009 Mar;24(3):334–40. [PMC free article] [PubMed]
12. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ, Adult AIDS Clinical Trials Group Cardiovascular Subcommittee HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Sep 1;37(5):613–27. [PubMed]
13. Stein JH. Managing Cardiovascular Risk in Patients with HIV Infection. J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):115–23. [PubMed]
14. Seoane L, Shellito J, Welsh D, deBoisblanc BP. Pulmonary hypertension associated with HIV infection. South Med J. 2001 Jun;94(6):635–9. [PubMed]
15. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS. 2008 Sep;22 3:S55–62. [PubMed]
16. Nayak G, Ferguson M, Tribble DR, Porter CK, Rapena R, Marchicelli M, Decker CF. Cardiac Diastolic Dysfunction is Prevalent in HIV-Infected Patients. AIDS Patient Care STDs. 2009 Mar 13; Epub ahead of print. [PubMed]
17. Lipshultz SE, Chanock S, Sanders SP, Colan SD, Perez-Atayde A, McIntosh K. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol. 1989 Jun 15;63(20):1489–97. [PubMed]
18. The P2C2 HIV Study Group. The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus infection study: design and methods. J Clin Epidemiol. 1996;49(11):1285–94. [PMC free article] [PubMed]
19. Starc TJ, Lipshultz SE, Easley KA, Kaplan S, Bricker JT, Colan SD, Lai WW, Gersony WM, Sopko G, Moodie DS, Schluchter MD. Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P2C2 HIV study. J Pediatr. 2002 Sep;141(3):327–34. [PMC free article] [PubMed]
20. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Colan SD. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Circulation. 2000 Sep 26;102(13):1542–8. [PMC free article] [PubMed]
21. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD, Working Group 3 Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008 Jul 8;118(2):e36–40. [PubMed]
22. Zareba KM, Lavigne JE, Lipshultz SE. Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol. 2004;4(3):271–9. [PubMed]
23. Lipshultz SE, Shearer WT, Thompson B, et al. Antiretroviral therapy (ART)-associated cardiotoxicity in uninfected by ART-exposed infants born to HIV-infected women: the prospective NHLBI CHAART-I study. Abstract Pediatric Academic Society Annual Meeting. 2006
24. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Shevitz A. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr. 2008 Oct;153(4):491–7. [PMC free article] [PubMed]
25. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: Executive Summary. Circulation. Jul 8;118(2):198–210. [PMC free article] [PubMed]